Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/61947

Title2´OMethylRNA EFG1 antisense oligomer to control Candida albicans filamentation
Author(s)Araújo, Daniela
Azevedo, N.
Barbosa, Ana
Almeida, Carina
Rodrigues, M. Elisa
Henriques, Mariana
Silva, Sónia Carina
Issue date14-Oct-2019
CitationAraújo, Daniela; Azevedo, N.; Barbosa, Ana; Almeida, Carina; Rodrigues, M. Elisa; Henriques, Mariana; Silva, Sónia Carina, 2OMethylRNA EFG1 antisense oligomer to control Candida albicans filamentation. 15th Annual Meeting of the Oligonucleotide Therapeutics Society. Munich, Germany, Oct 13-16, 114, 2019.
Abstract(s)Antisense oligomers (ASO) and their analogues have been successfully utilized to silence gene expression for the treatment of many human diseases, however the control of yeast´s virulence determinants have never been exploited before. In this sense, this work is based on the key hypothesis that if a pathogens genetic sequence is a determinant of virulence, it will be possible to synthesize a nucleic acid mimic based on antisense therapy (AST) that will bind to the mRNA produced, blocking its translation into protein and consequently reducing the pathogen virulent phenotype. EFG1 is an important determinant of virulence that is involved in regulation of Candida albicans switch from yeast to filamentous form. Thus, our main goal was to design and synthesize an ASO targeting the EFG1 mRNA and to validate its in vitro applicability in order to control C. albicans filamentation. For that, an ASO against EFG1 was designed, including 2OMethylRNA chemical modification, through bioinformatic tools. The fluorescence in situ hybridization (FISH) was performed and demonstrated that the ASO was able to penetrate Candida cell wall with high sensitivity and specificity. To determine the effect of anti-EFG1 2OMe, the gene level expression, protein translation inhibition and reduction of filamentation reduction were analysed. The results show that the anti-EFG1 2OMe oligomer was able to significantly reduce the levels of EFG1 gene expression (around 58%) and of Efg1p protein translation (approximately 56%), as well as effectively prevent filamentation of C. albicans cells (by 80%). Moreover, it was verified that anti-EFG1 2OMe keep the efficacy in different simulated human body fluids. Undeniably, this work provides potentially valuable information for future research into the management of Candida infections, regarding the development of a credible and alternative method to control C. albicans infections, based on AST methodology.
TypePoster
URIhttp://hdl.handle.net/1822/61947
Publisher versionhttps://www.oligotherapeutics.org/2019-annual-meeting/
Peer-Reviewedyes
AccessOpen access
Appears in Collections:CEB - Painéis em Conferências / Posters in Conferences

Files in This Item:
File Description SizeFormat 
document_52168_1.pdf216,51 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID